Optimal treatment of complicated skin and skin structure infections

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue TOPIC A, 1999, Pages 19-23

  Nichols, Ronald Lee ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; HUMAN; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 0032867146     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.suppl_1.19     Document Type: Review

References (32)

1. Baquero, F. (1997). Gram-positive resistance: challenge for the development of new antibiotics. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 1-6.
2. Voss, A. & Doebbeling, B. N. (1995). The worldwide prevalence of methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 5, 101-6.
3. Gaynes, R. P., Culver, D. H., Horan, T. C., Henderson, T. S., Tolson, J. S. & Martone, J. (1993). Trends in methicillin-resistant Staphylococcus aureus in the United States' hospitals. Infectious Diseases in Clinical Practice 2, 452-5.
4. Favero, M. S., Gaynes, R. P., Horan, T. C., Emori, T. G., Stroud, L. A., Archibald, L. K. et al. (1996). National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986-April 1996. American Journal of Infection Control 24, 380-8.
5. Nichols, R. L. (1996). Surgical infections: prevention and treatment - 1965 to 1995. American Journal of Surgery 172, 68-74.
6. Hong, J. & Davis, J. M. (1996). Nosocomial infections and nosocomial pneumonia. American Journal of Surgery 172, Suppl. 6A, 33-7S.
7. Horan, T. C., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Edwards, J. R. & Reid, C. R. (1993). Nosocomial infections in surgical patients in the United States, January 1986-June 1992. Nosocomial Infections Surveillance (NNIS) System. Infection Control and Hospital Epidemiology 14, 73-80.
8. Romero-Vivas, J., Rubio, M., Fernandez, C. & Picazo, J. J. (1995). Mortality associated with nosocomial bacteraemia due to methicillin-resistant Staphylococcus aureus. Clinical Infectious Disease 21, 1417-23.
9. Turnidge, J. & Grayson, M. L. (1993). Optimum treatment of staphylococcal infections. Drugs 45, 353-66.
10. Vincent, J. L., Bihari, D. J., Suter, P. M., Bruining, H. A., White, J., Nicolas-Chanoin, M. H. et al. (1995). The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Journal of the American Medical Association 274, 639-44.
11. Hiramastsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, E. C. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40, 135-6.
12. Hiramatsu, K. (1998). The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. American Journal of Medicine 104, Suppl 5A, 7-10S.
13. Centers for Disease Control and Prevention. (1997). Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report 46, 765-6.
14. Centers for Disease Control and Prevention. (1997). Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbidity and Mortality Weekly Report 46, 813-5.
15. Ploy, M. C., Grelaud, C., Martin, C., de Lumley, L. & Denis, F. (1998). First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351, 1212.
16. Gentry, L. O. & Koshdel, A. (1989). Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious Gram-negative infections of skin and skin structure. American Journal of Medicine 87, Suppl. 5A, S132-5.
17. Gentry, L. O. & Rodriguez-Gomez, G. (1993). Ofloxacin treatment of difficult infections of the skin and skin structure. Cutis 51, 55-8.
18. Goldstein, F. W. & Acar, J. F. (1995). Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49, Suppl. 2, 36-42.
19. Aldridge, K. E., Glefand, M. S., Schiro, D. O. & Barg, N. L. (1992). The rapid emergence of fluoroquinolone methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents. Diagnostic Microbiology and Infectious Disease 15, 601-8.
20. Durlach, R. A., Bantar, C., Freuler, C., Nicola, F., Laugas, S. & Smayevsky, J. (1997). Efficacy of teicoplanin (IV q 48 h) for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. In Abstracts of the IDSA Thirty-Fifth Annual Meeting. Abstract 442, p. 154. Infectious Disease Society of America, San Francisco, USA.
21. Edelstein, H. E., Oster, S. E,. Chirurgi, V. A., Karp, R. A., Cassano, K. B. & McCabe, R. E. (1991). Intravenous or intramuscular teicoplanin once daily for skin and soft tissue infections. Drug Intelligence and Clinical Pharmacy 25, 914-8.
22. Fernandez-Guerrero, M., Gobernado, M., Ariza, J. & Williams, A. (1990). Spanish experience with teicoplanin. Scandinavian Journal of Infectious Diseases Supplement 72, 38-44.
23. Okada, H., Okuda, M., Kashima, M. & Takahashi, H. (1993). Clinical study of teicoplanin in dermatology. Chemotherapy 41, Suppl. 2, 264-6.
24. Yura, J. & Kukita, A. (1993). Clinical evaluation of teicoplanin in the treatment of skin and soft tissue infections. Chemotherapy 41, Suppl. 2, 134-45.
25. Kanzaki, H., Shimoe, K., Arata, J. & Umemura, S. (1993). Use of teicoplanin in the field of dermatology. Chemotherapy 41, Suppl. 2, 267-9.
26. Nathwani, D., Reid, T. M. S., Gould, I. M., Golder, D., Smith, C. C. & Douglas, J. G. (1991). An open study of teicoplanin in the treatment of Gram-positive infections. Journal of Chemotherapy 3, 315-20.
27. Wood, M. J. (1996). The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 209-22.
28. Gruneberg, R. N. (1997). Anti-Gram-positive agents. What we have and what we would like. Drugs 54, Suppl. 6, 29-38.
29. Polk, R. E. (1998). Red man syndrome. Annals of Pharmacotherapy 32, 840.
30. Mainardi, J. L., Schlaes, D. M., Goering, R. V., Schlaes, J. H., Acar, J. F. & Goldstein, F. W. (1995). Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. Journal of Infectious Diseases 171, 1646-50.
31. Nichols, R., for the US Synercid SSSI Study Group. (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (oxacillin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2319. International Society of Chemotherapy.
32. Beal, J., for the Global Synercid SSSI Study Group. (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2318. International Society of Chemotherapy.